CAV1 and pancreatic neoplasm: A recent study by Kamposioras et al. showed that when genetically modified stromal cells were co-injected with tumor cells in a pancreatic cancer model [114], the tumor growth rate was accelerated, and resistance to gemcitabine developed when CAV1 was silenced [114].